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Deadly Discounts: How Reimportation Jeopardizes the Safety of the U.S. Pharmaceutical
Drug Supply under the Federal Trade Commission Amendment

By Nicole Bates
Summary
This paper analyzes a pharmaceutical reimportation amendment not yet up for
vote in the U.S. Congress. The amendment to a Federal Trade Commission (FTC)
reauthorization bill, previously introduced as Senate Bill 334 (S.334) Pharmaceutical
Market Access and Drug Safety Act of 2005 allows for the reimportation of prescription
drugs into the United States from approximately 25 countries, including Canada via
Internet pharmacies. There are no guarantees that the internet websites advertising as
Canadian pharmacies are legitimate. The shipping of pharmaceutical drugs occurs
through importation, which refers to drugs produced abroad then later shipped to the
U.S., or re-importation, a term applied when drugs are produced in the U.S. and exported
for sale to foreign countries and later imported back into the U.S.
The amendment attempts to open the border doors even further by allowing
increased importation of medicine and requires pharmacies and drug wholesalers to
register with the FDA. The potential importers will be subject to frequent, random
inspection; however, these inspections are inadequate and more must be done. Some real
solutions include electronic pedigrees and authentication technologies. Also, technology
must be rotated so that illegitimate manufacturers can not adapt and overcome anticounterfeiting measures.
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I. Introduction
Across the world, people get sick everyday. From the common cold to cancer
treatment, people seek medicines that will ease their pain and suffering. But what
happens when those medicines we rely on to relieve our symptoms, in turn, actually end
up causing more side effects? Is there a way to actually know whether your medicine is
real or a fraud?
An amendment to the Federal Trade Commission (FTC), formerly known as
Senate Bill (S.334) Pharmaceutical Market Access and Drug Safety Act of 2005, brings
this issue to the forefront. Supporters of the amendment argue that since the price of U.S.
prescription drugs are rapidly increasing, citizens should be allowed to look outside of the
country for cheaper alternatives. The U.S. Congress found that senior citizens will spend
$1,800,000,000,000 on pharmaceuticals over the next ten years. Therefore, lawmakers
can give foreign pharmaceutical markets the chance to offer U.S. citizens cheaper
alternatives.1 Research shows that the average brand name drug in Canada is 38%
cheaper than it would be if bought in the U.S.2
This sounds great of course. Nobody would argue there is a problem with saving
money. However, the problem arises when the discount may cost people their lives.
Congress argues that allowing medicine from outside markets into our country could save
American consumers at least $38,000,000,000 each year.3 There is no denying that the
cost of medicine is high in the United States, largely due to the fact price controls are
1

Pharmaceutical Market Access and Drug Safety Act of 2005, S.334, 109th Cong. §2(5) [hereinafter
known as S.334].
2
Abraham N. Saiger, In Search of a Government that Will Govern: Senate Bill 812 and “Reimporting”
Prescription Medication from Canada, 12 Elder L.J. 177, 179 (2004)(discussing the current state of affairs
of medication prices in both the U.S. and Canada).
(citing Press Release, Office of Sen. Dorgan (D-N.D.), U.S. Consumers Pay Substantially Higher Prices for
Their Medications than Consumers in Canada and Other Countries).
3
S.334 supra note 1, at §2(6) .
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non-existent; but, the question then becomes, do people want to pay the high price for
medicine or would they rather risk opening the floodgates of weakly regulated drugs into
our country? Which is the better choice of the two evils?
The amendment, not yet up for Congressional vote, attempts to prevent
counterfeit drugs from entering the U.S. One method of regulation is requiring monthly
inspections of imported medicines. This is a positive step but more must be done to
adequately address the problem. Currently, the amendment actually allows more
medicine to enter into the country because more than 25 countries would be allowed to
import medicine into the U.S. The medicines from outside the U.S. cannot be guaranteed
under FDA standards, thus, increasing the likelihood of fakes entering our healthcare
system. Several other problems remain and are discussed below.
The topic of counterfeit medicines is new and evolving everyday with cases of
fake medicines found in many countries throughout the world. This paper will introduce
the major topic areas and analyze the amendment attempts to combat this growing
problem in the U.S. This article will also take the position that the amendment should not
be passed by Congress. Instead, Congress needs to take a serious look at the multiple
risks associated with reimportation and incorporate more safety features into a new bill.

II. Reimportation
Reimportation is the practice of importing pharmaceutical drugs across the border
from Canada4. The majority of the drugs are manufactured originally in the United States

4

Jennifer L. Halser, Canadian Pharmacies: A Prescription for a Public Health Disaster, 54 DePaul L.Rev
543, 544 (2005) (explaining the practice of reimportation)[hereinafter Halser].
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by U.S. pharmaceutical companies and then distributed to Canadian pharmacies5.
Reimportating prescription drugs from Canada is currently illegal but is quickly
becoming popular with U.S. citizens, especially the elderly6.
Approximately one million Americans cross the Canadian border annually to buy
prescription drugs at low prices7. Others visit Canadian pharmacies via the Internet or
frequent U.S. stores like Rx Depot, Inc. that sell imported Canadian drugs at Canadian
prices across the United States8. In 2003, the amount of reimportation activity was
predicted to be worth $800 million9. Consumers can save between 32% and 57% on
commonly purchased prescription drugs when purchasing them from Canadian
pharmacies10.
The FDA has “enforcement discretion” which permits reimportation as outlined in
the FDA’s Coverage of Personal Importations document11. The FDA can and has
allowed individual patients to import small prescriptions of drugs when the drug is not
available in the U.S.12 However, reimportation is not allowed under most circumstances,
and the FDA has sent warning letters to Canadian pharmacies yet only one Canadian
pharmacy, Rx Depot, Inc., has been shut down13.
Despite the regulations on reimportation, politicians are beginning to create
reimportation programs for their constituents and are already importing in record

5

Id.
Id.
7
Chad D. Silker, America’s New War on Drugs: Should the United States Legalize Prescription Drug
Reimportation?, 31 J. Legis 379, 379 (2005) (discussing the many forms of reimportation) [hereinafter
Silker].
8
Id.
9
Halser, supra note 4.
10
Id.
11
Silker, supra note 7, at 383.
12
Id.
13
Halser, supra note 4, at 545.
6

5

numbers14. At the center of the reimportation issues is the amendment to the FTC
reauthorization bill discussed in Section IV. There are very serious problems and
consequences that come with reimportation since the supply chain is not always clear and
safe. The medicine supposedly from Canada can come from anywhere, and U.S. citizens
must be informed about all the risks involved with reimportation. At the forefront of
those risks, is the chance medicine entering the U.S. is counterfeit.

III. Counterfeiting: What is it?
Counterfeit medicines are deliberately and fraudulently mislabeled medicines as
to identity and/or source.15 Production, distribution, and sale of counterfeit medicines
have all substantially increased in recent years.16 Annual earnings from counterfeit and
substandard medicine sales are over $32 billion globally.17 Yet, this number may be even
larger since no global study has ever been conducted.18
By contrast, genuine medicines are medicines with correct packaging and the
correct quantity of ingredients.19 Substandard medicines have genuine packaging but
contain an incorrect quantity of ingredients (not deliberate).20 Counterfeit medicines are
the result of any of the following: mislabeling drugs (such as a fake expiration date), no

14

Halser, supra note 4, at 545.
World Health Organization, Regional Office for the Western Pacific, available at
http://www.wpro.who.int/health_topics/counterfeit_medicines/general_info.htm (last visited July 19,
2005)[hereinafter known as WHO Regional Office].
16
Id.
17
World Health Organization Media Centre: Substandard and Counterfeit Medicine, available at
http://www.who.int/mediacentre/factsheets/fs275/en/index.html (last visited on May 18, 2005) [hereinafter
WHO Media Centre].
18
World Health Organization, Essential Drugs and Medicines Policy: Counterfeit Medicines: Overview
available at
http://www.who.int/medicines/organization/qsm/activities/qualityassurance/cft/CounterfeitOverview.htm
(last visited on July 27, 2005).
19
WHO Regional Office, supra note 15.
20
Id.
15
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active ingredients, wrong ingredients, correct ingredient and insufficient quantity of
correct ingredients.21 Both brand name and generic products can be counterfeited.22
An example of counterfeit medicine was reported to the World Health
Organization in 2002 when bottles of the HIV drug Combivir were found to actually
contain another HIV medicine, Ziagen.23 This type of counterfeiting could have caused
potentially life-threatening hypersensitivity reactions to HIV patients unaware of what
they were taking since there was a possibility of deadly drug interactions with other
medicines the patients were taking.24

A. Global Problems: Counterfeiting on an International Level
The importation of medicine, weaknesses in the economy, and reductions in
health benefits have contributed to the rise in counterfeiting.25 Counterfeiting is a bigger
problem in developing countries and national measures alone have not been proven
adequate to combat this activity.26 International measures are necessary to combat this
growing threat. In April 1999, 771 cases of substandard medicines entered into WHO
database, 77% from developing countries.27 According to the World Health
Organization, more than 10% of medicine on the global market is counterfeit with nearly
25% of the medicine in developing countries being counterfeit or substandard.28 This

21

Id.
Id.
23
WHO Media Centre, supra note 17.
24
Id.
25
Pfizer, Counterfeit Q & A, available at
http://www.pfizer.com/subsites/counterfeit_importation/mn_faq_counterfeiting.html (last visited on May
10, 2005)[hereinafter known as Pfizer Q & A].
26
WHO Regional Office, supra note 15.
27
WHO Media Centre, supra note 17.
28
World Health Organization, Western Pacific Region, Rapid Alert System: Combating Counterfeit
Medicines, available at http://218.111.249.28/ras/default.asp?tag=19& (last visited on July 14, 2005).
22
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number may be even larger since experts have estimated 60% of developing countries
medicines are counterfeit.29
The consequences of counterfeit medicines are deadly. The results range from
therapeutic failure to drug resistance to death. When the 1995 meningitis epidemic broke
out in Niger, 50,000 people where inoculated with fake vaccines which caused 2,500
deaths.30 In 1995, cough syrup prepared with diethylene glycol, a toxic chemical used in
antifreeze led to 89 deaths in Haiti and 30 infant deaths in India in 1998.31 A study
conducted in South-East Asia in 2001 revealed that 38% of 104 anti-malarial drugs on
sale in pharmacies did not contain any active ingredients and had resulted in a number of
preventable deaths.32
China is widely regarded as the world leader in terms of manufacturing and
exporting counterfeit products.33 In 2001, 192,000 Chinese people died due to fake
drugs.34 Since 2001, Johnson & Johnson have built 38 criminal cases against Chinese
factories that manufactured copies of its products.35

B. Counterfeit Medicines Harm the United States
Why is counterfeiting medicine even a problem in the United States? The U.S. is
an industrialized and modern country and has an entire Department of Health and Human
29

International AntiCounterfeiting Coalition, White Paper: The Negative Consequences of International
Intellectual Property Theft: Economic Harm, Threats to the Public Health and Safety, and Links to
Organized Crime and Terrorist Organizations (January 2005) available at www.iacc.org/WhitePaper.pdf
(last visited on June 28, 2005) [hereinafter known as White Paper] (citing The Engineer, Fighting the
Fakers, at 16 (April 26, 2002); Phillippe Broussard, Dangerous Fakes, World Press Review, v44, n1, p36
(1) (January 1999)).
30
WHO Media Centre, supra note 17.
31
Id.
32
Id.
33
White Paper, supra note 29 (citing China’s Killer Headache: Fake Pharmaceuticals, Washington Post
(August 30, 2002)).
34
White Paper, supra note 29.
35
Id.
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Services dedicated to keeping U.S. citizens safe with the creation of the Food and Drug
Administration (FDA). However, over the years, counterfeit medicine has crept into our
borders through reimportation.36 The amendment attempts to open the border doors even
further by allowing increased importation of medicine. However, the risks are high to
public health, the economy, and to U.S. safety against terrorism.

1. Public Health
In 2004, The FDA’s Office of Criminal Investigations (OCI) initiated 58 cases of
counterfeit drugs compared to 30 cases in 2003.37 Although the FDA believes the U.S.
drug supply is one of the safest in the world, they agree that more work needs to be done
to secure the national drug supply.38
Each year, U.S. citizens fill more than three billion prescriptions through
pharmacies they believe are reputable and assume their medicine is safe.39 In 2001,
Americans spent an estimate $140.6 billion on outpatient prescription drugs40. However,
as the following examples show, patients do not always get what they need.
In May 2003, the FDAalerted U.S. consumers that approximately 200,000 bottle s
of counterfeit Lipitor, a medicine for patients with high cholesterol levels, were on the

36

LillyAnswers, Needy seniors don’t have to buy medications from other countries, available at
http://www.lillyanswers.com/en/drug_issues.html (last visited on July 27, 2005)[hereinafter LillyAnswers].
37
U.S. Food and Drug Administration, Combating Counterfeit Drugs: A Report of the Food and Drug
Administration Annual Update (May 18, 2005), available at
http://www.fda.gov/oc/initiatives/counterfeit/update2005.html (last visited on July 27, 2005)[hereinafter
known as FDA Update 2005].
38
Id.
39
Katherine Eban, Dangerous Doses: How Counterfeiters Are Contaminating America’s Drug Supply pg 110 (2005)[hereinafter Dangerous Doses].
40
Silker, supra note 7.
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market.41 To date, eight people have been indicted and four have pled guilty while
another was convicted by a jury trial.42
In 2001, three people were arrested in Los Angeles for copying the packaging, the
packaging inserts, and the lot numbers of Pfizer’s Viagra.43 In 2002, seven people and
five companies in the U.S., China, and India were charged with selling fake Viagra via
the Internet after undercover officers bought over 25,000 pills.44 One supplier even told
an undercover agent that he could supply 2.5 million pills a month. Some of the pills
were smuggled into the U.S. by hiding them in stereo speakers and stuffed toys.45
In 2005, a California man pled guilty to illegal trafficking more than $5.6 million
in fake Viagra tablets.46 Frank Fu Jen Huang, 58, admitted to importing counterfeit
Viagra tablets manufactured in China. Customs officials intercepted four of his shipments
with more than 30,000 pills.47 Huang sold some of the product to an associate, David
Srulevitch, 55, who then resold the fake Viagra.48 After the shipments were seized,
Huang and Srulevitch manufactured approximately 700,000 fake Viagra tablets in a
California laboratory.49

41

White Paper, supra note 18 (citing Peter Jaret, Fake Drugs, Real Threat, Los Angeles Times at F1
(February 4, 2004)).
42
FDA Update 2005 supra note 37.
43
White Paper, supra note 29 (citing Douglas Pasternak, Knockoffs on the Pharmacy Shelf, Counterfeit
Drugs are Coming to America, U.S. News & World Report at 26 (June 11, 2001)).
44
White Paper, supra note 29 (citing Ridgely Ochs, Sounding Alarm on Counterfeit Drugs; FDA
Investigating Recent Faking Drug Cases, New York Newsday, at 6 (June 12, 2002)).
45
Id.
46
San Gabriel Tribune, Sentencing Delayed in Fake Viagra Case (March 28, 2005), available at
http://www.sgvtribune.com/Stories/0,1413,205~12220~2787232,00.html (last visited July 31, 2005).
47
Id.
48
Id.
49
Id.
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In 2004, another man admitted to conspiracy to manufacture and import
thousands of counterfeit Viagra pills into the U.S. from Beijing.50 He was sentenced to
18 months in prison with 3 years probation and fined $6000.51
Many of the drugs used by U.S. citizens are lifestyle drugs such as Viagra.
Unlike the manufacturer Pfizer’s Viagra, the generic Viagra has misled many people and
is considered illegal by the FDA and potentially dangerous because it may contain
inappropriate substances that at first have positive effects but then turn into severe
consequences.52
Generic Viagra is not considered legal to sell or buy in the US and a web site
offering “generic Viagra” or “generic sildenafil citrate” is illegal.53 Pfizer recommends
that the only way to know a patient is receiving genuine medicine is to buy from a
National Association of Boards of Pharmacy (NABP) Verified Internet Pharmacy
Practice Sites (VIPPS) certified online pharmacy.54
Investigative journalist Katherine Eban’s book Dangerous Doses examines the
lives of three U.S. patients who received fake drugs during the course of treatment for a
transplant, cancer, and AIDS.55 One of those patients is Timothy Fagan, a 16 year-old
living in New York, who received eight weeks of injections of what doctors thought to be
the correct dose of Epogen after a liver transplant.56 The injections were given to treat

50

FDA Update 2005, supra note 37.
Id.
52
American Viagra Pharmacies Online, What is Generic Viagra and the Difference between Pfizer Viagra
and Generic Viagra?, available at http://www.american-viagra-pharmacies.com/genericviagra.html (last
visited on July 19, 2005).
53
Id.
54
Pfizer Q & A, supra note 25.
55
Dangerous Doses, supra note 39.
56
Id.
51
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his anemia and raise his red blood cell count.57 However, over the course of his
treatment, Fagan grew worse as he suffered from painful aches and spasms58. The
doctors treating Fagan were surprised to see that the 40,000 units of Epogen they
prescribed were ineffective. The reason for this was that the injections turned out to
contain only 2,000 units.59

2. Terrorist/Organized Crime
Epogen was also at the center of another controversy when a criminal ring relabeled approximately 110,000 bottles of Epogen to give the appearance it contained
dosages of Procrit, a drug twenty times stronger than Epogen. (WP) The Florida Bureau
of Statewide Pharmaceutical Services estimated the counterfeiters profit at around $46
million.60
Terrorists and organized crime groups have been pirating goods for years to raise
money for their activities. Both types of organizations need to create and maintain steady
sources of funding and are attracted to counterfeiting since it can be financially rewarding
and anonymous.61 Because of the low risk of prosecution and large profits, the FBI states
that counterfeiting is an “attractive enterprise for organized crime groups.”62

57

Id.
Id.
59
Id.
60
Office of Program Policy Analysis and Government Accountability (OPPAGA) an office of the Florida
Legislature, Justification Review: Counterfeit and Diverted Drugs Threaten Public Health and Waste State
Dollars (February 2003), available at http://www.oppaga.state.fl.us (last visited on May 18,
2005)[hereinafter known as Justification Review].
61
White Paper, supra note 29.
62
See http://www.fbi.gov/hq/cid/fc/fifu/about/about_ipc.htm (last visited on May 19, 2005).
58
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The September 11, 2001 attacks on the World Trade Center cost roughly
$500,000 to pull off the hijacking of two planes, around $26,000 per terrorist.63 This
amount of money is not hard to get if one pirates any type of good, including medicine.
Discs with pirated music found in Paraguay by investigators contained cards with images
of the World Trade Center exploding and Osama Bin Laden.64 Though the monetary
source of the September 11th attacks has not been traced, it is quite possible that terrorists
looked to counterfeiting goods or medicines as a quick and easy way to fund their
activities.
Terrorist groups have already profited from counterfeiting according to a 2003
report stating the Irish Republican Army (IRA) has produced counterfeit Ivomec, a
livestock anti-parasite drug, to get money for weapons.65 The lab that produced the fake
drug was found in Florida and the fake labels were produced on a farm in Northern
Ireland.66
All it takes is a terrorist group to start manufacturing and sending out a few
rounds of legitimate medicine from a home-based laboratory with counterfeit labels.
After the product has entered the market and the group has not been caught for fake
labels, there is nothing to stop terrorists from slipping a deadly chemical into bottles of
cough syrup or headache pills.

63

White Paper, supra note 29 (citing Katherine Macklem, The Terror Crisis has Lit a Fire under Ottawa’s
Lagging Anti-lanundering Effort, MacLean’s, October 22, 2001 at 62).
64
White Paper, supra note 29 (citing Statement of Iain Grant before the House International Relations
Committee, Hearing on Intellectual Property Crimes: Are Proceeds from Counterfeited Goods Funding
Terrorism (July 16, 2003) available at http://wwwc.house.gov/international_relations/108/88392.pdf (pg
48-49) (last visited on August 1, 2005)).
65
White Paper, supra note 29 (citing Global Options, Inc. & Reconnaissance International Report, An
Analysis of Terrorist Threats to America’s Medicine Supply at 66-67 & nn. 138-39 (2003)).
66
Id.
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To prevent something like this from happening, the U.S. must deter criminals
with stiffer penalties. Counterfeiters must know that there are dire consequences in
manufacturing fake medicines.

3. No Accountability
There is little deterrence for those who are involved in counterfeiting and selling
fake medicine. There are no uniform sentencing guidelines, and the ones in place need
altering.67
In 2005, Stephen Lewis, who ran a fraudulent Internet pharmacy using drugs from
an illegal San Diego operation, was sentenced to two years in jail and fined only $5,000
for conspiracy to sell unapproved drugs and conspiracy to launder money.68 His wife
Pamela Lewis was sentenced to serve five months in jail with five months of home
detention and ordered to pay only a $2,000 fine for conspiracy to sell unapproved drugs.
69

The San Diego judge ordered the couple to forfeit their bank account holdings as well

as the profit from selling their home, roughly $150,000.70
However, the website MyRxForLess, run by the Lewis’s, sold between $1 million
and $2.5 million worth of medication in two years according to the U.S. Attorney’s

67

See FDA Update 2005, supra note 37 (Increased criminal penalties deter counterfeiting and more
adequately punish those convicted. Although increased criminal penalties would not affect FDA's
regulatory framework for overseeing the U.S. drug supply, they would provide an added deterrent to
criminals who work to counterfeit our citizens' medications. FDA has requested that the United States
Sentencing Commission amend the sentencing guidelines to increase substantially the criminal penalties for
manufacturing and distributing counterfeit drugs and to provide for enhanced penalties based on the level
of risk to the public health involved in the offense).
68
S.D. Judge Sentences Couple in Internet Pharmacy Case, by Sarah Skidmore, San Diego Union Tribune,
available at http://www.signonsandiego.com/news/business/20050518-9999-1b18webrx.html (last visited
May 18, 2005).
69
Id.
70
Id.
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Office.71 The website operated out of Lake Worth, Florida but claimed the medications
were from a reputable Mexican pharmacy when in actuality, people who worked for
Stephen Lewis bought the drugs in Mexico and mailed them to customers.72 San Diego
resident Mark Kolowich, who ran his own illegal pharmaceutical business, assisted the
couple’s business by shipping fake Viagra and Cialis to customers.73 Kolowich pled
guilty to charges and was sentenced to 51 months in prison and was made to forfeit cash
profits.74

4. Economic
There are also economic ramifications of counterfeiting. A weak economy has
people looking elsewhere for money making ideas when the unemployment rate is up. In
1996, U.S. losses from counterfeiting and piracy in general were estimated by the
International Trade Commission to be around $200 billion.75
There are high profits in counterfeiting, which creates a large loss of tax revenue
with New York City losing $1.03 billion in lost tax revenue in 2003 due to intellectual
property theft.76

71

Id.
Id.
73
Id.
74
Id.
75
White Paper, supra note 29 (citing S.Rep.No. 104-177, 104th Cong., 1st Sess. 1-2 (1995)).
76
Thompson: Counterfeiting Costs NYC more than $1 Billion Annually, The New York City Office of the
Comptroller Press Release (November 22, 2004), available at
http://www.comptroller.nyc.gov/press/2004_releases/print/pr04-11-065.shtm (last visited on July 12,
2005).
72
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IV. Cheaper Alternatives: Why They Exist and Where
A. United States Free Market
The U.S. is a free market having no price controls.77 On the other hand, Canada
and the numerous other countries Congress is allowing to import into the U.S. have
implemented government-set prices on prescriptions. If companies do not follow this
government control, they are forced to pay fines or risk the revocation of intellectual
property.78 Price controls affect the amount of new scientific ideas for medicine. Until
the 1970’s, Europe developed most of the world’s medicines.79 However, by 2003, the
U.S. developed eight out of the world’s top 10 selling drugs.80

B. Research and Development Costs
It costs more than $800 million and 10-15 years to bring a new medicine to
market with most medicines being developed by private U.S. research-based
pharmaceutical manufacturers, not government laboratories.81 In 2003, Pharmaceutical
Research and Manufacturers of America member companies invested an estimated $33.2
billion on research to develop new medicine- 17.7% of domestic sales.82 This research
and development to sales ratio is higher than any other U.S. industry.83 Yet, there needs

77

LillyAnswers, supra note 36.
Id.
79
Id.
80
Id.
81
Pharmaceutical Research and Manufacturers of America: Intellectual Property, available at
http://www.phrma.org/issues/intprop/ (last visited on July 27, 2005).
82
Pharmaceutical Research and Manufacturers of America: Research and Development, available at
http://www.phrma.org/issues/researchdev/ (last visited on July 27, 2005).
83
Id.
78
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to remain new research and development since new medicines help control health care
costs.84

C. Canadian Internet Pharmacies and Mexican Border Towns
Internet sales of pharmaceuticals make it easy for U.S. citizens to obtain
inexpensive medicines, sometimes without a prescription. There is a current trend in the
U.S. for citizens to buy prescriptions from Internet websites claiming they are reputable
Canadian pharmacies.
There are several problems with this practice. First and foremost, the drugs may
still be counterfeit.85 In fact, the medicine can come from anywhere, since there are no
guarantees that a website is actually based in Canada just because it claims to be.86
According to a report by GlobalOptions Inc., a security consulting firm, approximately
1/3 of purported Canadian websites were actually not from a Canadian host.87 The U.S.
FDA cannot guarantee the safety of Canadian medicine since importation of it increases
the likelihood of altered or mishandled medicines reaching U.S. citizens.88 Lastly,
medicines imported from Canada via the internet are also not subject to government
health and safety checks.89
In 2003, the FDA and U.S. Customs and Border Protection conducted random
searches of mailed pharmaceutical drugs into Miami, New York, and San Francisco.90

84

Pharmaceutical Research and Manufacturers of America: Publications, available at
http://www.phrma.org/publications/policy/24.04.2004.983.cfm (last visited on July 27, 2005).
85
LillyAnswers, supra note 36.
86
Id.
87
Id.
88
Id.
89
Before You Buy Canadian Drugs: What you need to know, available at http://www.BuySafeDrugs.info
(last visited July 6, 2005).
90
LillyAnswers, supra note 36.
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Of the 1,153 imported drugs, 88% were in violation of U.S. federal pharmaceutical safety
or efficacy standards.91
The FDA also warns consumers against buying medicine in Mexican border
towns since purchasers can not assume the products meet the “quality, efficacy, and
safety standards of FDA authorized products or that FDA is assuring the quality, safety,
and efficacy of products purchased from outside the United States.”92

V. A Proposed Solution: The Amendment to the FTC Legislation
The sections above have laid out a basic sketch of what the global and national
counterfeiting issues are. The U.S. Congress has decided to take action to combat
growing drug prices while still maintaining a safe pharmaceutical market for its citizens.
The following section analyzes the amendment to determine whether the amendment
provides an adequate solution to the growing problem of counterfeit medicine.

A. Explanation and Analysis of the Amendment
On July 21, 2005 Senators Bryon L. Dorgan (D-N.D) and Olympia Snowe (RME) won approval by the Senate Commerce Committee on a 14-8 vote to allow an
amendment to theFTC reauthorization bill .93 The amendment, previously known as
S.334 Pharmaceutical Market Access and Drug Safety Act of 2005, is a bi-partisan
attempt to address the issue of importing prescription drugs into the U.S. Three

91

Id.
U.S. Food and Drug Administration, FDA Talk Paper: FDA Warns Consumers About Counterfeit Drugs
Purchased in Mexico, available at http://fda.gov/bbs/topics/ANSWERS/2004/ANS01303.html (last visited
on May 18, 2005).
93
News Release, Dorgan, Snowe Win Vote to Allow Re-Importation of Lower Priced Prescription Drugs,
available at http://Dorgan.senate.gov/newsroom/record.cfm?id=241180 (last visited on August 15, 2005).
92
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provisions from separate bills (S.109) mandate that packages for reimported prescription
drugs use counterfeit-resistant technologies and designate even more countries that can
provide medicine to the U.S. if Canada restricts sales to the U.S.94 The amendment was
introduced for a number of reasons but a main objective was to alleviate the costs of
prescription drugs for U.S. citizens.95

1. Importation from More Countries
The amendment allows U.S. licensed pharmacies and drug wholesalers to import
medications approved by the FDA from Canada, 90 days after the amendment’s passage.
Europe (nations that were members of the EU as of January 1, 2003), Australia, New
Zealand, and Japan would be allowed to import one year after the bill’s passage date.96
This would then allow U.S. citizens to buy drugs from these countries and receive their
discounted prices while still using a local U.S. pharmacy.97 However, allowing more
medicine to enter into the country, since approximately 25 countries could import to the
U.S., increases the likelihood of fakes entering our healthcare system. The exact path a
medicine takes before it comes into the U.S. is often unknown.
Under the amendment, individuals can import prescription drugs for personal use
and consumers can receive drugs via mail from Canadian pharmacies 90 days after its
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enactment.98 Yet, as statedabove , there is no way to guarantee these internet websites
advertising as Canadian pharmacies are who they purport to be. Further, there are no
guarantees the medicine was not altered in some way before reaching a U.S. citizen’s
doorstep.

2. Safety Measures
The most important aspect the amendment lacks is adequate safety measures.
Congress must take a hard look at the serious lack of protection this amendment provides
to the American people.

a. Licensing/Registration
The proposed safety features of the amendment require pharmacies and drug
wholesalers to register with the FDA.99 Exporters must give their name and identify all
places of business that relate to qualifying drugs, including every warehouse or facility
that is owned, controlled by, or operated for the exporter.100
The Secretary of Health and Human Services states the following requirements
are necessary from a registrant exporter: inspection of facilities and the marking of
compliant shipments, payment of fees, licensed as a pharmacist, conditions for individual
importation, and maintenance of records and samples.101 The Secretary will provide a list
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of registered exporters, with contact information, through the FDA’s website and a toll
free number.102
Pharmacists and wholesalers that reimport prescription drugs have to pay fees as
much as 1% of the price of the medicine to fund the costs of federal inspectors and agents
that will need to document the authenticity of the medicines entering the U.S.103
If the amendment passes, U.S. citizens will be able to order prescription drugs in
the mail from Canadian pharmacies 90 days after the passage.104 With all the drugs
coming in from Canada, there is impossible to inspect the shipments to make sure every
single one of them are from registered exporters. The amendment allows citizens to
purchase drugs via the Internet from Canada, then from several other countries in the next
year. Once an exporter is registered under the amendment, the exporter is free to deliver
medicine to U.S. citizens after paying a small fee. Afterwards, there will be no stopping
the flood of unregulated medicine entering into the country.

b. Inspections
Exporters are subject to frequent, random inspections.105 However, even if an
exporter’s place of business is inspected once a month, a producer of counterfeit can
resume legitimate manufacturing while FDA inspectors are on the premises then start
producing fake pills once the inspectors leave the site. In some cases, a foreign exporter
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will have warning that a U.S. FDA representative is coming to visit their plant since word
of mouth might put the exporter on notice.
The U.S. should retain the ability to have access to inspectors as witnesses in
criminal cases and the amendment must be changed to allow the FDA the ability to
inspect foreign establishments even where the FDA has instituted agreements with
foreign regulatory agencies.

c. Chain of Custody
Importation of medicines must also have a “chain of custody” that allows the
FDA to trace the medicine all the way back to a manufacturer that has been approved and
inspected by the FDA.106 A chain of custody refers to the “combining (of) electronic and
physical capabilities to create situational awareness about an item’s past and future as it
moves through the supply chain.”107 This is necessary but the amendment does not
establish how it will combat fraudulent paperwork or counterfeit pedigrees. Fake
paperwork is easy to create and the amendment fails to take a hard look at what
technology is needed to provide a true and accurate chain of custody.
Under the amendment, pedigrees are not required when there are supposedly no
other intervening transactions from the manufacturer to the distributor.108 However, there
are no guarantees that no intervening transactions occurred or even that the transaction
paperwork is genuine.
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B. Closing the Gaps of the Amendment
1. Fixing the Problem Domestically
Instead of letting citizens go to other countries to find cheaper drugs, the U.S.
needs to seriously look at why its drug prices are so out of control. There are no price
controls. There are no limits to what pharmaceutical manufacturers can charge for
medicine in the U.S.
Everybody can look for discounted prescription programs that are available to
lower income families or individuals (such as http://www.rxassist.org/,
http://www.peopleschoicerx.com/, or http://www.togetherrx.com/).
Starting January 1, 2006, Medicare will implement a prescription drug plan that
will work for its users to help alleviate prescription costs and pay over half of patient’s
drug costs.109 Local churches and charities will often help with prescription drug costs as
well. There are many ways for citizens to find discounts within the FDA approved U.S.
borders without logging onto Canadian websites.

2. Funding
In order to fully regulate the practice of importing from this many countries, there
needs to be adequate funding from the Secretary of Health and Human Services. It is
unknown exactly how much is needed to create a system that is able to randomly inspect
shipments from countries but some have suggested that the system would be fully
financed by user fees of registered importers and Canadian exporters with fees capped at
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1%.110 Still, meeting the FDA requirements to ship medicine into the U.S. will increase
the discounted price. Again, instead of spending money to inspect foreign drugs, pass on
the discount to U.S. citizens on drugs they can buy within the country.

3. No Criminal Deterrence for Foreign Companies
Other problems with the amendment include a weak framework of drug
regulation with states and federal systems. There are no criminal penalties when
counterfeiting medicines occurs within U.S. borders and the financial incentives alone are
enough to encourage a person to risk getting caught in exchange for making millions of
dollars. The WHO has noted that fear of arrest and prosecution and the leniency of penal
sanction encourage counterfeiting even more.111 There are several problems associated
with prosecuting companies shipping illegal drugs because prosecution is likely to
involve extensive coordination between governments even if all of the countries involved
have developed legal systems.112 For prosecutions of foreign companies shipping illegal
drugs into the U.S. and violating inspection standards, the U.S. must be able to a) gather
evidence abroad b) gain the cooperation of witnesses in a foreign legal system who may
face possible prosecution in their own countries c) produce competent evidence gathered
abroad in a U.S. trial that demonstrates culpability beyond a reasonable doubt and d)
overcome the legal barriers of jurisdiction and extradition so that the process can be
executed.113
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Investigation of illegal actions abroad is difficult because grand jury subpoenas do
not allow for service abroad except for citizens or residents of the United States.114 Yet,
there are other ways to gather evidence such as letters rogatory or mutual legal assistance
treaties.115 Letters rogatory are requests from a judge in the U.S. to the judiciary of a
foreign country requesting the performance of an act, which if done without the sanction
of the foreign court, would violate the country’s sovereignty.116 Mutual legal assistance
treaties have the force of law and are faster and more reliable than letters rogatory.117
The amendment should be amended to reach criminal as well as jurisdictional
powers over any foreign company and individuals who are allowed to import drugs into
the United States. Since the companies are subjecting themselves to U.S. standards and
importation regulations, companies caught shipping illegal drugs should subject
themselves to the law of the U.S.

4. Lack of a Jurisdictional Section in the Amendment
When medicine is counterfeited and imported into the Congress has jurisdictional
power to address the problem of counterfeit drugs when the conduct occurs overseas. In
international law, courts may use several legislative jurisdiction options including
territorial, national, passive personality, protective, and universal jurisdiction. However,
Congress has not implemented a necessary jurisdictional section in the amendment that
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would allow courts to prosecute.118 Congress must put in place a type of long arm statute
to reach outside of U.S. borders to be able to prosecute violators of the amendment.

VI. Real Solutions
A. Improving Technology
It is imperative that new technologies are implemented to protect the U.S. drug
supply and provide greater security to the general public.

1. Tracking and Tracing with Electronic Pedigrees
Pedigrees are written sales history that traces each drug back to its initial
manufacturer which provides an “audit trail” that should contain detailed information
about each sales transaction.119 For example, each pedigree should contain the name and
address of each purchaser of the drug.120 The Prescription Drug Marketing Act (PDMA)
of 1987 established the requirement of pedigree papers as a minimum standard for the
prescription drug wholesale industry to prevent drug diversion and counterfeiting.121 In
the example of the criminal ring caught counterfeiting Procrit in Florida, the group resold
the counterfeit drugs into the wholesale market with forged pedigree papers and passed
the drugs through four states and four wholesalers.122 Forging papers are pretty simple.
This is where electronic pedigrees come in.
Radiofrequency Identification (RFID) is the tagging of products by
manufacturers, wholesalers, and retailers that provides reliable product tracking and
118
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tracing.123 The FDA states that reliable RFID technology will make counterfeiting
medicines extremely difficult or unprofitable and is the most promising approach to
reliable product tracking and tracing.124 Studies have started to confirm that RFID will
provide cost-reducing benefits in areas like inventory control.125 Supporters of RFID also
hope that it will also provide the ability to track and trace the movement of every package
of drugs from the production line to its distribution.126
RFID provides an electronic pedigree that surpasses the intent of PDMA and at a
lower cost with the FDA stating more effective electronic pedigrees can be implemented
within several years.127

2. Authentication Technologies
Authentication technologies such as color shifting inks, holograms, fingerprints,
taggants, or chemical markers embedded in a drug or the label is an important part of an
effective anti counterfeiting strategy.128 However, the FDA acknowledges that
counterfeiters adapt quickly to roadblocks and the most effective use of authentication
technology is to vary it by product over time.129
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3. Additional Support
A national list has also been developed by the National Drug Advisory Coalition
which includes 31 drugs that are mostly likely to be counterfeited that will also help in
deterring counterfeiting.130
It is important to note that no single measure, not even electronic pedigrees, can
provide adequate protection from counterfeiting.131 Technology must be rotated so that
illegitimate manufacturers can not adapt and overcome anti-counterfeiting measures.

B. States and Stiffer Penalties
States license and regulate wholesale drug distributors currently.132 The FDA and
National Association of Boards of Pharmacy (NABP) are currently developing Model
Rules for Licensure of Wholesale Drug Distributors so that illegitimate wholesalers will
find it difficult to become licensed and transact business, thus, making it easier to prevent
counterfeit drugs from entering our system.133 Four states have laws in place similar to
the Model Rules (California, Florida, Indiana, and Nevada) and other states are
considering adoption (Iowa, New Jersey).134 The NABP also created the VerifiedAccredited Wholesale Distributors (VAWD) program to complement the Model Rules.135
Applicants for VAWD accreditation must undergo a criteria compliance review, licensure
verification, an inspection, background checks, and screening through NABP’s
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clearinghouse.136 This accreditation process provides assurances that wholesale
distribution facilities are legitimate, validly licensed in good standing, and employ the
best practices for safely distributing drugs from manufacturers.137
Increased criminal penalties are also necessary and provide an additional deterrent
to counterfeiters and adequately punish convicted counterfeiters based on the level of risk
to public health.138 Some states, like Florida, are recommending that state legislatures
should raise criminal penalties involving counterfeit prescription drugs and drug
diversion to second degree felonies.139 Strengthening accountability within the drug
distribution system through tougher enforcement and stiffer penalties is another way to
improve the situation.140 As stated previously, there shouldn’t be different penalties for
forging a trademark and forging medicine. Putting a fake drug on the market not only
harms people but it undermines the entire healthcare system.

C. Working Together: Global Solutions to a Global Problem
Counterfeiting medicines that designed to help reduce the pain and suffering of
patients is a growing problem. However, this problem is not seen only in certain areas of
the world. Sick people live in every city, state, country, and continent so it is impossible
for this not to be a global issue that must be addressed in a uniform manner across the
world.
The WHO in the Western Pacific Region is working on a regional strategy calling
for increased awareness of health care providers, policymakers, and the general public
136
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through a regional rapid alert system as well as through stronger collaboration between
medicine regulatory authorities and law enforcement agencies.141 The FDA has also
stated their intentions to work with the WHO, Interpol, and other international public
health and law enforcement organizations to develop and implement worldwide strategies
to combat the problem of counterfeit drugs.142 In March 2005, representatives from the
FDA attended a conference held by the Pan-American Health Organization (PAHO)
where the FDA found its efforts to combat counterfeit drugs consistent with those of
PAHO.143
The FDA’s Office of Criminal Investigations (OCI) trained foreign law
enforcement, customs and judicial officers in the U.S. Patent and Trademark Office
Intellectual Property Enforcement Academy on how to combat counterfeit drugs. (43)
It is essential that countries work together to combat the counterfeiting of
medicine since it is such a global issue. World leaders must make this a priority when
setting national agendas since fake medicines continue to harm and even kill citizens of
countries across the world.

D. Consumer Awareness
Buy from VIPPS websites only, report suspected counterfeiting to 1-800-FDA1088 and to the manufacturer, watch out if the price of medicine seems too good to be
true, do not buy from online pharmacies that offer to sell medication without
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prescriptions, talk to your pharmacist if you notice anything different about your
medicine or its effects on you.144

VII. Conclusion
The amendment is the solution our lawmakers have come up with to try to solve
the problem of high drug prices. But in doing so, they have actually heightened the risk
of creating an unsafe medicine supply.
There are so many examples of counterfeit medicines that have been either
imported into the U.S. or manufactured within U.S. borders. Before we start opening the
doors to allow other countries to import prescription medicine, the country needs to first
address the current state of affairs. Why do we need to open the country up to more
counterfeit drugs? Some argue because they are cheaper than ours. So, why not make
U.S. pharmaceuticals affordable? Others would then argue that research and
development would suffer since the U.S. is the major contributor to R & D costs. One
must weigh the pros and cons. The pros- the availability of cheap drugs, people can
remain healthy or benefit from prescriptions when they are able to afford the medicine
they need. The cons- the risks of receiving a fake medicine include not getting the
miracle of the miracle drugs because there are no active ingredients, aggravated
symptoms, or even death. Other risks include economic harm and terrorists possibly
tainting the drug supply.
In the end, the fact remains that counterfeit drugs have been and will continue to
harm people in the U.S. and abroad. It is up to Congress to decide when the amendment
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comes up for a vote, whether the proposed the amendment is enough protection to keep
us safe.
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